[{"address1": "Gooimeer 2-35", "city": "Naarden", "zip": "1411 DC", "country": "Netherlands", "phone": "31 35 206 2971", "website": "https://www.newamsterdampharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.", "fullTimeEmployees": 68, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael Harvey Davidson FACC, Facp., M.D.", "age": 69, "title": "CEO, President & Executive Board Member", "yearBorn": 1956, "fiscalYear": 2024, "totalPay": 1122237, "exercisedValue": 0, "unexercisedValue": 51427864}, {"maxAge": 1, "name": "Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.", "age": 71, "title": "Founder, Chief Scientific Officer, Member of Executive Board & Director", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 813077, "exercisedValue": 4094829, "unexercisedValue": 35092304}, {"maxAge": 1, "name": "Mr. Mayur Amrat Somaiya", "age": 51, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 841238, "exercisedValue": 0, "unexercisedValue": 3954412}, {"maxAge": 1, "name": "Mr. Douglas F. Kling", "age": 52, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 913742, "exercisedValue": 0, "unexercisedValue": 17441960}, {"maxAge": 1, "name": "Ms. Juliette  Audet M.B.A., M.Sc.", "age": 38, "title": "Chief Strategy & Business Officer", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 653039, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Louise  Kooij", "age": 49, "title": "Chief Accounting Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Philippe", "title": "Executive VP &Head of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bob  Rambo", "title": "Executive Vice President of Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maryellen  McQuade", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Ditmarsch M.D.", "age": 58, "title": "Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 32.06, "open": 32.78, "dayLow": 32.15, "dayHigh": 34.74, "regularMarketPreviousClose": 32.06, "regularMarketOpen": 32.78, "regularMarketDayLow": 32.15, "regularMarketDayHigh": 34.74, "payoutRatio": 0.0, "beta": 0.069, "forwardPE": -20.087526, "volume": 531834, "regularMarketVolume": 531834, "averageVolume": 892090, "averageVolume10days": 577740, "averageDailyVolume10Day": 577740, "bid": 24.88, "ask": 41.31, "bidSize": 2, "askSize": 2, "marketCap": 3889304320, "fiftyTwoWeekLow": 14.06, "fiftyTwoWeekHigh": 42.0, "allTimeHigh": 42.0, "allTimeLow": 5.633, "priceToSalesTrailing12Months": 110.35679, "fiftyDayAverage": 34.6778, "twoHundredDayAverage": 27.8747, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3186624512, "profitMargins": 0.0, "floatShares": 62439780, "sharesOutstanding": 113390804, "sharesShort": 6319202, "sharesShortPriorMonth": 6258439, "sharesShortPreviousMonthDate": 1765756800, "dateShortInterest": 1768435200, "sharesPercentSharesOut": 0.0557, "heldPercentInsiders": 0.00468, "heldPercentInstitutions": 1.05935, "shortRatio": 7.53, "shortPercentOfFloat": 0.0664, "impliedSharesOutstanding": 113390804, "bookValue": 6.433, "priceToBook": 5.3318825, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -221072992, "trailingEps": -2.04, "forwardEps": -1.7075273, "enterpriseToRevenue": 90.419, "enterpriseToEbitda": -15.719, "52WeekChange": 0.7808931, "SandP52WeekChange": 0.14272952, "quoteType": "EQUITY", "currentPrice": 34.3, "targetHighPrice": 60.858154, "targetLowPrice": 37.717495, "targetMeanPrice": 48.751137, "targetMedianPrice": 47.5, "recommendationMean": 1.35714, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 13, "totalCash": 702945984, "totalCashPerShare": 6.199, "ebitda": -202720000, "totalDebt": 266000, "quickRatio": 12.411, "currentRatio": 12.567, "totalRevenue": 35243000, "debtToEquity": 0.037, "revenuePerShare": 0.311, "returnOnAssets": -0.20697, "returnOnEquity": -0.39943, "grossProfits": 35243000, "freeCashflow": -69113504, "operatingCashflow": -144388992, "revenueGrowth": -0.988, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -158.45691, "financialCurrency": "USD", "symbol": "NAMS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "NewAmsterdam Pharma Company N.V.", "marketState": "CLOSED", "exchange": "NGM", "messageBoardId": "finmb_685404834", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 6.98689, "regularMarketPrice": 34.3, "shortName": "NewAmsterdam Pharma Company N.V", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612881000000, "postMarketChangePercent": 0.0, "postMarketPrice": 34.3, "postMarketChange": 0.0, "regularMarketChange": 2.24, "regularMarketDayRange": "32.15 - 34.74", "fullExchangeName": "NasdaqGM", "corporateActions": [], "postMarketTime": 1770412204, "regularMarketTime": 1770411600, "epsTrailingTwelveMonths": -2.04, "epsForward": -1.7075273, "epsCurrentYear": -1.32858, "priceEpsCurrentYear": -25.817038, "fiftyDayAverageChange": -0.3778, "fiftyDayAverageChangePercent": -0.010894578, "twoHundredDayAverageChange": 6.4252987, "twoHundredDayAverageChangePercent": 0.23050646, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2022-11-23", "averageAnalystRating": "1.4 - Strong Buy", "cryptoTradeable": false, "averageDailyVolume3Month": 892090, "fiftyTwoWeekLowChange": 20.239998, "fiftyTwoWeekLowChangePercent": 1.4395446, "fiftyTwoWeekRange": "14.06 - 42.0", "fiftyTwoWeekHighChange": -7.700001, "fiftyTwoWeekHighChangePercent": -0.18333335, "fiftyTwoWeekChangePercent": 78.08931, "earningsTimestampStart": 1762349400, "earningsTimestampEnd": 1762349400, "isEarningsDateEstimate": false, "displayName": "NewAmsterdam Pharma Company", "trailingPegRatio": null, "__fetch_time": "2026-02-07"}]